Shuford Kathryn, Were Florence, Awino Norbert, Samuels Aaron, Ouma Peter, Kariuki Simon, Desai Meghna, Allen Denise Roth
Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
Kenya Medical Research Institute (KEMRI), Kisian, Kenya.
Malar J. 2016 Feb 6;15:71. doi: 10.1186/s12936-016-1123-y.
Intermittent mass screening and treatment (iMSaT) is currently being evaluated as a possible additional tool for malaria control and prevention in western Kenya. The literature identifying success and/or barriers to drug trial compliance and acceptability on malaria treatment and control interventions is considerable, especially as it relates to specific target groups, such as school-aged children and pregnant women, but there is a lack of such studies for mass screening and treatment and mass drug administration in the general population.
A qualitative study was conducted to explore community perceptions of the iMSaT intervention, and specifically of testing and treatment in the absence of symptoms, before and after implementation in order to identify aspects of iMSaT that should be improved in future rounds. Two rounds of qualitative data collection were completed in six randomly selected study communities: a total of 36 focus group discussions (FGDs) with men, women, and opinion leaders, and 12 individual or small group interviews with community health workers. All interviews were conducted in the local dialect Dholuo, digitally recorded, and transcribed into English. English transcripts were imported into the qualitative software programme NVivo8 for content analysis.
There were mixed opinions of the intervention. In the pre-implementation round, respondents were generally positive and willing to participate in the upcoming study. However, there were concerns about testing in the absence of symptoms including fear of covert HIV testing and issues around blood sampling. There were fewer concerns about treatment, mostly because of the simpler dosing regimen of the study drug (dihydroartemisinin-piperaquine) compared to the current first-line treatment (artemether-lumefantrine). After the first implementation round, there was a clear shift in perceptions with less common concerns overall, although some of the same issues around testing and general misconceptions about research remained.
Although iMSaT was generally accepted throughout the community, proper sensitization activities-and arguably, a more long-term approach to community engagement-are necessary for dispelling fears, clarifying misconceptions, and educating communities on the consequences of asymptomatic malaria.
目前正在评估间歇性群体筛查和治疗(iMSaT)作为肯尼亚西部疟疾控制和预防的一种可能的补充工具。关于疟疾治疗和控制干预措施中药物试验依从性和可接受性的成功因素和/或障碍的文献很多,特别是涉及学龄儿童和孕妇等特定目标群体的文献,但缺乏针对普通人群群体筛查和治疗以及群体药物管理的此类研究。
开展了一项定性研究,以探讨社区对iMSaT干预措施的看法,特别是在实施前后对无症状检测和治疗的看法,以便确定iMSaT在未来轮次中应改进的方面。在六个随机选择的研究社区完成了两轮定性数据收集:与男性、女性和意见领袖进行了总共36次焦点小组讨论(FGD),并与社区卫生工作者进行了12次个人或小组访谈。所有访谈均使用当地的多洛语进行,进行数字录音,并转录为英语。英语转录本被导入定性软件程序NVivo8进行内容分析。
对该干预措施的看法不一。在实施前的一轮中,受访者总体上持积极态度,并愿意参与即将开展的研究。然而,对于无症状检测存在担忧,包括对秘密艾滋病毒检测的恐惧以及采血相关问题。对治疗的担忧较少,主要是因为与目前的一线治疗药物(蒿甲醚 - 本芴醇)相比,研究药物(双氢青蒿素 - 哌喹)的给药方案更简单。在第一轮实施后,看法发生了明显转变,总体担忧减少,尽管围绕检测的一些相同问题以及对研究的普遍误解仍然存在。
尽管iMSaT在整个社区中普遍被接受,但需要开展适当的宣传活动,并且可以说,需要采取更长期的社区参与方法来消除恐惧、澄清误解,并就无症状疟疾的后果对社区进行教育。